Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jul;40(7):1623–1627. doi: 10.1128/aac.40.7.1623

Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.

H Klinker 1, P Langmann 1, E Richter 1
PMCID: PMC163384  PMID: 8807051

Abstract

Steady-state plasma pyrimethamine levels were measured by gas chromatography. The specimens were taken from 74 adults with advanced human immunodeficiency virus infection receiving pyrimethamine-containing drugs for prophylaxis or curative therapy of reactivated cerebral toxoplasmosis. During an overall treatment period of 1,049 months, 1,012 plasma samples were investigated. Pyrimethamine concentrations could be evaluated in 904 plasma samples. The weekly dosage of pyrimethamine ranged from 25 to 1,400 mg; one patient with severe diarrhea received 2,100 mg/week. Steady-state plasma pyrimethamine concentrations were achieved after 12 to 20 days. Pyrimethamine concentrations evidently increased with the weekly dosage given. Mean concentrations were 253 +/- 151 ng/ml with 50 mg of pyrimethamine per week, 471 +/- 214 ng/ml with 100 mg of pyrimethamine per week, 1,893 +/- 1,182 ng/ml with 350 mg of pyrimethamine per week and 3,369 +/- 1,726 ng/ml with 1,050 mg of pyrimethamine per week. A widespread interpatient range was found for every dosage. With the simultaneous use of enzyme-inducing comedication, the plasma pyrimethamine levels decreased in several patients. Mild chronic liver disease did not influence plasma pyrimethamine concentrations. To avoid ineffective therapy or severe side effects, monitoring of pyrimethamine could be useful in patients receiving enzyme-inducing comedications and in patients with severe diarrhea or poor compliance.

Full Text

The Full Text of this article is available as a PDF (227.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araujo F. G., Guptill D. R., Remington J. S. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother. 1988 May;32(5):755–757. doi: 10.1128/aac.32.5.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Araujo F. G., Huskinson-Mark J., Gutteridge W. E., Remington J. S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother. 1992 Feb;36(2):326–330. doi: 10.1128/aac.36.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Araujo F. G., Remington J. S. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother. 1974 Jun;5(6):647–651. doi: 10.1128/aac.5.6.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bachmeyer C., Gorin I., Deleuze J., Morini J. P., Escande J. P. Pyrimethamine as primary prophylaxis of toxoplasmic encephalitis in patients infected with human immunodeficiency virus: open study. Clin Infect Dis. 1994 Mar;18(3):479–480. doi: 10.1093/clinids/18.3.479. [DOI] [PubMed] [Google Scholar]
  5. Cavallito J. C., Nichol C. A., Brenckman W. D., Jr, Deangelis R. L., Stickney D. R., Simmons W. S., Sigel C. W. Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. Drug Metab Dispos. 1978 May-Jun;6(3):329–337. [PubMed] [Google Scholar]
  6. Clumeck N., Sonnet J., Taelman H., Mascart-Lemone F., De Bruyere M., Vandeperre P., Dasnoy J., Marcelis L., Lamy M., Jonas C. Acquired immunodeficiency syndrome in African patients. N Engl J Med. 1984 Feb 23;310(8):492–497. doi: 10.1056/NEJM198402233100804. [DOI] [PubMed] [Google Scholar]
  7. Dannemann B., McCutchan J. A., Israelski D., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med. 1992 Jan 1;116(1):33–43. doi: 10.7326/0003-4819-116-1-33. [DOI] [PubMed] [Google Scholar]
  8. Fernandez-Martin J., Leport C., Morlat P., Meyohas M. C., Chauvin J. P., Vilde J. L. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1991 Oct;35(10):2049–2052. doi: 10.1128/aac.35.10.2049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grant I. H., Gold J. W., Rosenblum M., Niedzwiecki D., Armstrong D. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS. 1990 Jun;4(6):519–521. [PubMed] [Google Scholar]
  10. Harris C., Salgo M. P., Tanowitz H. B., Wittner M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis. 1988 Jan;157(1):14–22. doi: 10.1093/infdis/157.1.14. [DOI] [PubMed] [Google Scholar]
  11. Haverkos H. W. Assessment of therapy for toxoplasma encephalitis. The TE Study Group. Am J Med. 1987 May;82(5):907–914. doi: 10.1016/0002-9343(87)90151-3. [DOI] [PubMed] [Google Scholar]
  12. Jacobson M. A., Besch C. L., Child C., Hafner R., Matts J. P., Muth K., Wentworth D. N., Neaton J. D., Abrams D., Rimland D. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Infect Dis. 1994 Feb;169(2):384–394. doi: 10.1093/infdis/169.2.384. [DOI] [PubMed] [Google Scholar]
  13. Jones C. R., Ovenell S. M. Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim. J Chromatogr. 1979 Jun 11;163(2):179–185. doi: 10.1016/s0378-4347(00)81461-9. [DOI] [PubMed] [Google Scholar]
  14. Katlama C. Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):189–191. doi: 10.1007/BF01964459. [DOI] [PubMed] [Google Scholar]
  15. Le Liboux A., Duquesne H., Montay G., Chassard D., Pichard E., Thebault J. J., Frydman A., Gaillot J. Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/HPLC method. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:284–290. [PubMed] [Google Scholar]
  16. Leport C., Bastuji-Garin S., Perronne C., Salmon D., Marche C., Briçaire F., Vilde J. L. An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis. J Infect Dis. 1989 Sep;160(3):557–558. doi: 10.1093/infdis/160.3.557. [DOI] [PubMed] [Google Scholar]
  17. Leport C., Meulemans A., Robine D., Dameron G., Vildé J. L. Levels of pyrimethamine in serum and penetration into brain tissue in humans. AIDS. 1992 Sep;6(9):1040–1041. doi: 10.1097/00002030-199209000-00021. [DOI] [PubMed] [Google Scholar]
  18. Leport C., Raffi F., Matheron S., Katlama C., Regnier B., Saimot A. G., Marche C., Vedrenne C., Vilde J. L. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am J Med. 1988 Jan;84(1):94–100. doi: 10.1016/0002-9343(88)90014-9. [DOI] [PubMed] [Google Scholar]
  19. Luft B. J., Hafner R., Korzun A. H., Leport C., Antoniskis D., Bosler E. M., Bourland D. D., 3rd, Uttamchandani R., Fuhrer J., Jacobson J. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993 Sep 30;329(14):995–1000. doi: 10.1056/NEJM199309303291403. [DOI] [PubMed] [Google Scholar]
  20. Luft B. J., Remington J. S. AIDS commentary. Toxoplasmic encephalitis. J Infect Dis. 1988 Jan;157(1):1–6. doi: 10.1093/infdis/157.1.1. [DOI] [PubMed] [Google Scholar]
  21. Luft B. J., Remington J. S. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992 Aug;15(2):211–222. doi: 10.1093/clinids/15.2.211. [DOI] [PubMed] [Google Scholar]
  22. McLeod R., Mack D., Foss R., Boyer K., Withers S., Levin S., Hubbell J. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992 May;36(5):1040–1048. doi: 10.1128/aac.36.5.1040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Opravil M., Joos B., Lüthy R. Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob Agents Chemother. 1994 May;38(5):1197–1199. doi: 10.1128/aac.38.5.1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Remington J. S., Vildé J. L. Clindamycin for toxoplasma encephalitis in AIDS. Lancet. 1991 Nov 2;338(8775):1142–1143. doi: 10.1016/0140-6736(91)91997-9. [DOI] [PubMed] [Google Scholar]
  25. Ruf B., Schürmann D., Bergmann F., Schüler-Maué W., Grünewald T., Gottschalk H. J., Witt H., Pohle H. D. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 May;12(5):325–329. doi: 10.1007/BF01964427. [DOI] [PubMed] [Google Scholar]
  26. Saba J., Morlat P., Raffi F., Hazebroucq V., Joly V., Leport C., Vildé J. L. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1993 Nov;12(11):853–856. doi: 10.1007/BF02000407. [DOI] [PubMed] [Google Scholar]
  27. Solbreux P., Sonnet J., Zech F. A retrospective study about the use of cotrimoxazole as diagnostic support and treatment of suspected cerebral toxoplasmosis in AIDS. Acta Clin Belg. 1990;45(2):85–96. doi: 10.1080/17843286.1990.11718072. [DOI] [PubMed] [Google Scholar]
  28. Weidekamm E., Plozza-Nottebrock H., Forgo I., Dubach U. C. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull World Health Organ. 1982;60(1):115–122. [PMC free article] [PubMed] [Google Scholar]
  29. Weiss L. M., Harris C., Berger M., Tanowitz H. B., Wittner M. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis. 1988 Mar;157(3):580–583. doi: 10.1093/infdis/157.3.580. [DOI] [PubMed] [Google Scholar]
  30. Weiss L. M., Luft B. J., Tanowitz H. B., Wittner M. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am J Trop Med Hyg. 1992 Mar;46(3):288–291. doi: 10.4269/ajtmh.1992.46.288. [DOI] [PubMed] [Google Scholar]
  31. Zangerle R., Allerberger F., Pohl P., Fritsch P., Dierich M. P. High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii. Med Microbiol Immunol. 1991;180(2):59–66. doi: 10.1007/BF00193846. [DOI] [PubMed] [Google Scholar]
  32. Zilly W., Breimer D. D., Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):219–227. doi: 10.1007/BF00614021. [DOI] [PubMed] [Google Scholar]
  33. de Gans J., Portegies P., Reiss P., Troost D., van Gool T., Lange J. M. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J Acquir Immune Defic Syndr. 1992;5(2):137–142. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES